drugset / Trial / NCT04720378
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.
Timeline
- Start
- 2021-05-30
- Primary completion
- 2022-05-03
- Completion
- 2022-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ST266 | Protein / enzyme biologic | 0.1 unknown | Intravenous |
| Subject | ST266 | Protein / enzyme biologic | 0.25 unknown | Intravenous |
| Subject | ST266 | Protein / enzyme biologic | 0.5 unknown | Intravenous |
| Subject | ST266 | Protein / enzyme biologic | 1 unknown | Intravenous |